As a way to say thank you to the dedicated researchers who tirelessly work to advance the science and ultimately to improve the lives of the cancer genetics community, the journal is pleased to offer a 50% waiver on the article processing charges for select manuscripts published in Hereditary Cancer in Clinical Practice.
Before submitting your manuscript, and to receive editorial approval for the discount, please email the abstract of your manuscript to the Publishing Editor.
Hereditary Cancer in Clinical Practice is presenting a Collection on ‘Splicing Variants and Evidence For and Against Their Pathogenicity.' Splicing variants and their potential pathogenicity are important factors to consider in the development of hereditary cancer syndromes and rare diseases. This collection will comprise of recent research exploring the pathogenicity of splicing variants.
We are proud to announce that Hereditary Cancer in Clinical Practice is taking part in a new cross-journal collection: "Cancer Disparities". This collection aims to bring together articles enhancing our understanding of cancer health disparities across the different dimensions of inequality research. We welcome research, review, and correspondence articles that address key issues in the countries in which the authors are professionally engaged. This collection is now open for submissions.
Hereditary Cancer in Clinical Practice is an open access journal that publishes articles of interest for the cancer genetics community and serves as a discussion forum for the development appropriate healthcare strategies.
Cancer genetics encompasses a wide variety of disciplines and knowledge in the field is rapidly growing, especially as the amount of information linking genetic differences to inherited cancer predispositions continues expanding. With the increased knowledge of genetic variability and how this relates to cancer risk there is a growing demand not only to disseminate this information into clinical practice but also to enable competent debate concerning how such information is managed and what it implies for patient care. Read more.
This journal is participating in a pilot of NISO/STM's Working Group on Peer Review Taxonomy, to identify and standardize definitions and terminology in peer review practices in order to make the peer review process for articles and journals more transparent. Further information on the pilot is available here.
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: None
We welcome your feedback on this Peer Review Taxonomy Pilot. Please can you take the time to complete this short survey.
Discover the range of academic oncology titles at Springer Nature here.
Jan Lubinski is a Professor of Medicine and Head of the International Hereditary Cancer Center (organized in 1992) of Pomeranian Medical University in Szczecin, Poland. The center conducted the first world-wide population screening for cancer family syndromes in a 1.7 million region of West-Pomerania, Poland in 2000-2001. It has a network of outpatient clinics covering almost the entire country as well as a cancer bio-bank with biological samples and clinical data from 250,000 cancer cases and appropriate controls, which includes registries of thousands of mutation carriers.
Rodney J. Scott graduated from the University of Western Australia, Australia with a PhD in cellular biology and subsequently worked in the Department of Pathology and Laboratory Medicine at the University of Texas in Houston and then at the Centre for Teaching and Learning at the University of Basel, Switzerland. Since 1999 Prof. Scott has been a visiting Professor at the International Hereditary Cancer Center in Szczecin, Poland and more recently has been appointed as a adjunct Professor at the Universiti Kebangsaan Malaysia.
Hereditary Cancer in Clinical Practice is the official journal of the International Hereditary Cancer Center and is published under the auspices of International Union Against Cancer.
The Polish Ministry of Science and Higher Education and West Pomeranian Voivodeship (Województwo Zachodniopomorskie) provide funds for the publication of articles in this journal.
Citation Impact 2023
Journal Impact Factor: 2.0
5-year Journal Impact Factor: 1.9
Source Normalized Impact per Paper (SNIP): 0.569
SCImago Journal Rank (SJR): 0.729
Speed 2023
Submission to first editorial decision (median days): 5
Submission to acceptance (median days): 131
Usage 2023
Downloads: 394,813
Altmetric mentions: 196
Hereditary Cancer in Clinical Practice